IP Library Granted Patent US 8,182,788
Granted Patent B2
US 8,182,788 · App. 10/510,454 · Granted May 22, 2012

Method for obtaining a 2-

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,182,788
App. No.
10/510,454
Granted
May 22, 2012
Kind
B2
Abstract

The invention relates to a method for improving one or more physical/chemical characteristics, like reduced radiolysis of and the ability to autoclave, a 18F-fluor-deoxy-glucose (18F-FDG)-solution, which method comprises the steps of a) provision of a 18F-fluor-deoxy-glucose (18F-FDG)-solution, and b) addition of at least one buffer based on a weak acid to the 18F-fluor-deoxy-glucose (18F-FDG)-solution. The invention also relates to a method for preparing a sterile 18F-fluor-deoxy-glucose (18F-FDG)-solution by autoclaving said 18F-fluor-deoxy-glucose (FDG)-solution.

Claims (17)

1. A method for improving radiostability of a 18 F-fluor-deoxy-glucose ( 18 F-FDG)-solution during autoclaving, the method comprising:

a) providing a 18 F-fluor-deoxy-glucose ( 18 F-FDG)-solution,

b) adding at least one buffer based on a weak acid to the 18 F-fluor-deoxy-glucose ( 18 F-FDG)-solution, wherein the buffer is selected from the group consisting of citrate, acetate, ascorbate and combinations thereof; and,

c) autoclaving the buffered 18 F-fluor-deoxy-glucose ( 18 F-FDG)-solution.

2. The method according to claim 1 , wherein the buffered 18 F-FDG-solution maintains radiochemical purity after being autoclaved, thus rendering the solution suitable for medical applications.

3. The method according to claim 1 , wherein the pH of the citrate buffer is lower than 5.5.

4. The method according to claim 1 , wherein the pH of the acetate buffer is between 3.0 and 5.5.

5. The method according to claim 1 , wherein the pH of the ascorbate buffer is between 3.0 and 5.5.

6. The method according to claim 1 , wherein the buffered 18 F-fluor-deoxy-glucose (FDG)-solution is autoclaved at a temperature between 110° C. and 145° C.

7. The method according to claim 1 , wherein the buffered 18 F-fluor-deoxy-glucose (FDG)-solution is autoclaved at a temperature between 130° C. and 140° C.

8. The method according to claim 1 , wherein the buffered 18 F-fluor-deoxy-glucose (FDG)-solution is autoclaved at a temperature of 134° C.

9. The method according to claim 6 , wherein autoclaving is performed for a period of 1 to 30 minutes.

10. The method according to claim 6 , wherein autoclaving is performed for a period of 1 to 10 minutes.

11. The method according to claim 6 , wherein autoclaving is performed for a period of 2 to 5 minutes.

12. The method of claim 2 , wherein the radiochemical purity of the buffered 18 F-fluor-deoxy-glucose ( 18 F-FDG)-solution is at least 95%.

13. The method accordingly to claim 12 , wherein the radiochemical purity of the buffered 18 F-FDG-solution is at least about 95% 7.5 hours after being autoclaved.

14. The method according to claim 3 , wherein the pH of the citrate buffer is between 2 and 5.5.

Assignments (6)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 041131/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: MALLINCKRODT LLC
To: MALLINCKRODT NUCLEAR MEDICINE LLC
Reel/Frame 039149/0234 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2011
From: KNIGHT CASTRO, HECTOR HUMBERTO; KRUIJER, PETRUS SIMON
To: MALLINCKRODT INC.
Reel/Frame 025604/0286 →